W. R. Grace & Co. (Grace), a leading global specialty chemicals company, today announced the opening of its expanded fine chemical contract development and manufacturing (CDM) facility in South Haven, Michigan.

With 25% more capacity, the expansion makes room for a new 4,000-gallon HASTELLOY centrifuge and three 4,000-gallon, multi-use chemical reactors, strengthening Grace’s ability to serve growing demand for Active Pharmaceutical Ingredients (APIs).

"The newly expanded South Haven facility cements our position as a leading North American contract development and manufacturing organization (CDMO) and a leading employer in the community,” said Ed Sparks, Chief Executive Officer, Grace. “Equally important, the expansion solidifies our commitment to helping our fine chemical customers bring lifesaving and life-changing drug therapies to people everywhere.”

“The additional capacity and cutting-edge equipment in South Haven bolster our ability to grow with our current and future customers through every stage of fine chemical manufacturing – from research and development to clinical trials, scale-up services and commercial production of custom molecules and compounds,” said Brenda Kelly, President, Materials Technologies, Grace.

Serving the pharmaceutical market for more than 40 years, the South Haven facility produces APIs, regulatory starting materials (RSMs) and drug intermediates in quantities from kilos to tons, compliant with the FDA’s current Good Manufacturing Practice (cGMP) regulations.